Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma
对于符合移植条件的初诊多发性骨髓瘤患者,达雷妥尤单抗作为一线治疗方案具有成本效益。
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2021015220
Yamamoto, Chihiro; Minakata, Daisuke; Koyama, Shunsuke; Sekiguchi, Kaoru; Fukui, Yuta; Murahashi, Rui; Nakashima, Hirotomo; Matsuoka, Sae; Ikeda, Takashi; Kawaguchi, Shin-Ichiro; Toda, Yumiko; Ito, Shoko; Nagayama, Takashi; Umino, Kento; Nakano, Hirofumi; Morita, Kaoru; Yamasaki, Ryoko; Ashizawa, Masahiro; Ueda, Masuzu; Hatano, Kaoru; Sato, Kazuya; Ohmine, Ken; Fujiwara, Shin-Ichiro; Kanda, Yoshinobu